IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To determine the safety and effectiveness of clindamycin and primaquine in the treatment of mild Pneumocystis carinii pneumonia (PCP) in AIDS patients.
As many as 80 percent of AIDS patients experience at least one episode of PCP and about one-third of these patients have a recurrence of the disease. Drugs currently used for treatment of acute PCP are toxic to the majority of AIDS patients. The combination of clindamycin and primaquine reduces the numbers of PCP organisms in laboratory tests and in animal studies. Both drugs can be given orally, concentrate in lung tissue, and have been used safely in humans for treatment of other diseases. It is possible that the combination may prove to be as good or better than standard therapy for PCP and side effects may be less.
| Condition | Intervention |
|---|---|
| Pneumonia, Pneumocystis Carinii HIV Infections | Drug: Primaquine Drug: Clindamycin |
| Study Type: | Interventional |
| Study Design: | Masking: Open Label Primary Purpose: Treatment |
| Official Title: | The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS |
| Estimated Enrollment: | 50 |
| Study Completion Date: | November 1991 |
As many as 80 percent of AIDS patients experience at least one episode of PCP and about one-third of these patients have a recurrence of the disease. Drugs currently used for treatment of acute PCP are toxic to the majority of AIDS patients. The combination of clindamycin and primaquine reduces the numbers of PCP organisms in laboratory tests and in animal studies. Both drugs can be given orally, concentrate in lung tissue, and have been used safely in humans for treatment of other diseases. It is possible that the combination may prove to be as good or better than standard therapy for PCP and side effects may be less.
The proposal for the first 20 patients enrolled in ACTG 044 initially called for an open-labelled, pilot study of intravenous (IV) clindamycin and primaquine therapy in patients with mild to moderate PCP. Preliminary results of the first 22 patients entered into ACTG 044 indicate that the response rate to therapy was over 90 percent. The rate of discontinuation secondary to toxic side effects was only 20 percent. Additional uncontrolled studies have shown an excellent clinical response and safety profile in another 60 patients. The protocol has been amended to provide an all oral dosing regimen. An additional 20 patients with mild PCP will be enrolled and tested with oral clindamycin and primaquine on an outpatient basis. All patients will receive clindamycin and primaquine. Total duration of therapy will be 21 days. Patients may be hospitalized at any time during the study as clinically indicated. Treatment with zidovudine may be started or resumed after completion of clindamycin / primaquine therapy.
AMENDED: An additional 30 patients instead of 20 patients with mild PCP will be enrolled.
Eligibility| Ages Eligible for Study: | 13 Years and older (Child, Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
- Oral antiemetics.
Patients must have the following for inclusion:
- HIV positive by ELISA, p24 antigen or culture.
- Pneumocystis carinii pneumonia (PCP).
- Patients must have an (A-a) DO2 < 40 mmHg on room air.
- Willingness to sign an informed consent.
Prior Medication:
Allowed:
- Prophylaxis for Pneumocystis carinii pneumonia (PCP) with agents other than clindamycin and primaquine.
Exclusion Criteria
Concurrent Medication:
Excluded:
- Hematotoxic therapy, including zidovudine (AZT) or ganciclovir.
Patients with the following are excluded:
- History of allergy to clindamycin, lincomycin, or related drugs; or to primaquine or related drugs.
- Positive screen for G6PD deficiency, known NAD methemoglobin reductase deficiency, and/or known hemoglobin M abnormality.
- Concomitant conditions defined in Patient Exclusion Co-Existing Conditions.
- Any medical or social situation which, in the opinion of the investigator, would adversely affect participation in the study.
- Note:
Patients may be enrolled while G6PD screen is pending, but must be withdrawn if results are not known within 5 days after entry.
Prior Medication:
Excluded within 14 days of study entry:
- Systemic steroids at doses exceeding physiologic replacement or other investigational agents.
- Excluded within 6 weeks of study entry:
- Prior institution of any antiprotozoal therapy for the current episode of Pneumocystis carinii pneumonia or prophylaxis.
Patients must not have any of the following symptoms or diseases:
- History of allergy to clindamycin, lincomycin, or related drugs; or to primaquine or related drugs.
- Positive screen for G6PD deficiency, known NAD methemoglobin reductase deficiency, and/or known hemoglobin M abnormality.
- Diarrhea, defined as = or > 3 watery stools per day.
- Severe nausea and vomiting or other medical condition, such as ileus, that precludes oral therapy.
- Ventilator dependence or (A-a) DO2 = > 30 mm Hg.
- Any medical or social situation which, in the opinion of the investigator, would adversely affect participation in the study.
- Note:
Patients may be enrolled while G6PD screen is pending, but must be withdrawn if results are not known within 5 days after entry.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00000717
| United States, California | |
| Los Angeles County - USC Med Ctr | |
| Los Angeles, California, United States, 90033 | |
| San Francisco AIDS Clinic / San Francisco Gen Hosp | |
| San Francisco, California, United States, 941102859 | |
| United States, Illinois | |
| Northwestern Univ Med School | |
| Chicago, Illinois, United States, 60611 | |
| Rush Presbyterian - Saint Luke's Med Ctr | |
| Chicago, Illinois, United States, 60612 | |
| United States, Indiana | |
| Indiana Univ Hosp | |
| Indianapolis, Indiana, United States, 462025250 | |
| United States, Ohio | |
| Univ Hosp of Cleveland / Case Western Reserve Univ | |
| Cleveland, Ohio, United States, 44106 | |
| Ohio State Univ Hosp Clinic | |
| Columbus, Ohio, United States, 432101228 | |
| Study Chair: | Black JR |
More Information
Publications:
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00000717 History of Changes |
| Other Study ID Numbers: |
ACTG 044 11019 ( Registry Identifier: DAIDS-ES ) |
| Study First Received: | November 2, 1999 |
| Last Updated: | October 18, 2012 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
|
AIDS-Related Opportunistic Infections Pneumonia, Pneumocystis carinii Primaquine Infusions, Intravenous Drug Evaluation |
Drug Therapy, Combination Administration, Oral Acquired Immunodeficiency Syndrome Clindamycin |
Additional relevant MeSH terms:
|
HIV Infections Pneumonia Pneumonia, Pneumocystis Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections Lung Diseases, Fungal |
Mycoses Pneumocystis Infections Clindamycin Clindamycin palmitate Clindamycin phosphate Primaquine Anti-Bacterial Agents Anti-Infective Agents Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antimalarials Antiprotozoal Agents Antiparasitic Agents |
ClinicalTrials.gov processed this record on July 26, 2017